Publications by authors named "Maria Dorina G Bustos"
Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin-piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia.
Malar J
August 2023
Article Synopsis
- Dihydroartemisinin-piperaquine has been effective against uncomplicated Plasmodium falciparum malaria in Indonesia, but there's a slight increase in late treatment failures over time despite no artemisinin resistance observed.
- The research analyzed blood samples from malaria patients to investigate genetic markers for drug resistance, finding new SNPs but no SNPs linked to artemisinin resistance, and low levels of piperaquine resistance mutations.
- The findings suggest ongoing efficacy of the treatment, with most late failures attributed to reinfections rather than treatment failure, indicating that while resistance is not a major concern, continued monitoring is essential.
Article Synopsis
- Dihydroartemisinin-piperaquine (DHA-PPQ) has been used as the primary treatment for uncomplicated falciparum malaria in Indonesia since 2010, and its efficacy was assessed in two districts from April 2017 to April 2018.
- The study involved monitoring clinical and parasitological data over 42 days for patients treated with DHA-PPQ, following World Health Organization protocols, with 114 falciparum and 81 vivax cases eventually enrolled.
- Results showed a high efficacy of DHA-PPQ, with 93.1% of falciparum cases and 88.8% of vivax cases classified as adequately responding to treatment, with no significant delays in parasite clearance
Background: Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme.
View Article and Find Full Text PDFBackground: Emergence of artemisinin-resistant malaria in Southeast Asian countries threatens the global control of malaria. Although K13 kelch propeller has been assessed for artemisinin resistance molecular marker, most of the mutations need to be validated. In this study, artemisinin resistance was assessed by clinical and molecular analysis, including k13 and recently reported markers, pfarps10, pffd and pfmdr2.
View Article and Find Full Text PDFBackground: Anti-malarial drug resistance continues to be a leading threat to malaria control efforts and calls for continued monitoring of waning efficacy of artemisinin-based combination therapy (ACT). Artesunate + sulfadoxine/pyrimethamine (AS + SP) is used for the treatment of uncomplicated Plasmodium falciparum malaria in India. However, resistance against AS + SP is emerged in northeastern states.
View Article and Find Full Text PDFBackground: Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria.
Methods: This phase III, multi-center, comparative, open-label, parallel-group, controlled clinical trial included patients aged ≤12 years, bodyweight ≥5 to <25 kg, with a reported history of fever at inclusion or in the previous 24 h and microscopically-confirmed uncomplicated P.